Wall Street Journal - Thomas Gryta - 7 hours ago
... shows denosumab was superior to Novartis AG's (NVS) Zometa in preventing complications related to the spread of advanced prostate cancer to bones. ...
The researchers then used the microarray to scan blood samples from 58 patients with newly diagnosed breast, ovarian, or prostate cancer and from 39 age- ...
"Therefore, the major risk faced by prostate cancer patients is the development to metastasis." Gene modulation is a promising strategy to combat the ...
Factors responsible for invasive and metastatic progression of prostate cancer (PCa) remain largely unknown. Previously, we reported cloning of prosaposin ...
When the researchers restored the DAB2IP genetic function to metastatic prostate cancer cells, the EMT process reversed, thereby inhibiting the cancer ...
... expected this quarter, and data from a Phase III trial aiming to prevent bone metastases in prostate cancer patients are expected in the second half. ...
In the trial, the drugs were used to treat bone metastases in 1901 men with advanced prostate cancer, and denosumab was better than Zometa in delaying the ...
Prior studies have shown greater intake of saturated fat in red meat is associated with advanced prostate cancer and overall prostate cancer mortality. ...
Enrolment in the pivotal ALSYMPCA Phase III study in prostate cancer bone metastases is on track to complete this year, so the study should render results ...
Email this story